Le Dr Jean Daniel Arbour est directeur du département d’ophtalmologie de la faculté de médecine de l’Université de Montréal, où il est également professeur adjoint.

Après avoir fait un doctorat en médecine à l’Université de Montréal, un internat en chirurgie générale, puis des études spécialisées en ophtalmologie, il a suivi une formation clinique et chirurgicale en rétine à Harvard, aux États-Unis. Il y a aussi fait des recherches sur la dégénérescence maculaire ainsi qu’en thérapie photodynamique et antiangiogénique.

Il est actuellement chirurgien de la rétine et du vitré à l’Hôpital Notre-Dame du Centre hospitalier de l’Université de Montréal (CHUM), et fondateur de l’unité de recherche en ophtalmologie de ce même établissement. À ce titre, il a été chercheur principal dans plusieurs études internationales sur de nouveaux traitements de la dégénérescence maculaire et de la rétinopathie diabétique, ainsi que dans des études génétiques sur la DMLA exsudative. Auteur de plusieurs articles publiés dans diverses revues, il a donné, au cours des dernières années, plus de 70 conférences scientifiques au niveau national et international au sujet des maladies de la rétine.

Il a été président de l’Association des médecins ophtalmologistes du Québec de 2005 à 2009 et il est actuellement trésorier de la Société canadienne d’ophtalmologie.

Dr. Jean Daniel Arbour heads the ophthalmology department of the faculty of medicine at the University of Montreal, where he is also associate professor.

After receiving his M.D. from the University of Montreal, Dr. Arbour interned in general surgery, specialized in ophthalmology and then went to Harvard University in the United States for medical and surgical retina training. At Harvard, Dr. Arbour also conducted research on macular degeneration and photodynamic and antiangiogenic therapy.

Dr. Arbour is currently vitreoretinal surgeon at Notre-Dame Hospital, which is part of the University of Montreal hospital centre (CHUM). He is also the founder of the hospital’s ophthalmology research centre, where he has been the principal investigator in genetic studies of wet AMD and numerous international studies of new treatments in macular degeneration and diabetic retinopathy. The author of many articles published in medical journals, Dr. Arbour has also given more than 70 national and international scientific conferences on retinal disease.

Dr. Arbour was president of the Quebec association of ophthalmologists from 2005 to 2009. He is currently treasurer of the Canadian Ophthalmological Society.

If you are looking for local services or  treatment from your Local Ophthalmologist in the office or hospital from a Local Ophthalmologist, contact a provider such as ( Dr. Jean Daniel Arbour ) to inquire if they are accepting patients or you need a referral.   Phone number to book an appointment T 514 658 7217 F 514 419 9727

The speaker in the video may have no association with ( Dr. Jean Daniel Arbour, Local Ophthalmologist Montreal, QC ). 
( Dr. Jean Daniel Arbour, Local Ophthalmologist Montreal, QC ), may talk about some of the conditions and some of the treatment options shown on the videos. Always talk with your Local Ophthalmologist about the information you learnt from the videos in regards to treatments for What is Glaucoma? and procedures the Local Ophthalmologist could  perform and if they would be appropriate for you. Remember good information is the corner stone to understanding your condition or disease.

A local ophthalmologist is different from a local optometrist in that an optometrist doesn’t perform surgery. If you have a condition known as ocular hypertension, which is a result of high ocular pressure, your risk of developing glaucoma increases.Your optometrist or ophthalmologist may want to lower your IOP as a preventative measure.

Please contact ( Dr. Jean Daniel Arbour, Local Ophthalmologist Montreal, QC ) to enquire if this health care provider is accepting new patients.Patients are often concerned that an injection of material into their eye will be a painful or scary procedure. In fact, after the first or second injection, patients become quite at ease with the idea that they will have these injections, Following an intravitreal injection, you may feel pressure or grittiness in the eye, slight bleeding on the white of the eye and floaters in your vision. These are temporary and normal. As glaucoma progresses, it damages more and more of your optic nerve fibers, leading to vision loss. With primary open-angle glaucoma, the fluid can’t effectively flow back out of your eye. Angle-closure glaucoma occurs when the iris of the eye closes off the drainage angle completely, causing an increase in IOP pressure and damage to the optic nerve.

Glaucoma is a condition where there is increased pressure within the eyeball, causing damage to the optic nerve and gradual loss of sight.  If glaucoma is detected early preventative measures can be taken to save vision loss.

Cataracts can affect both eyes or just one, and some patients experience mild symptoms, while others can barely see any shapes or movements. Cataract symptoms include blurry vision, haloes, sensitivity to bright lights, decreased night vision, frequent changes in eyeglass prescriptions, and faded colours.

Glaucoma is a group of eye conditions that primarily affect the optic nerve, which transmits visual information from the retina to the brain. In most cases of glaucoma, damage to the optic nerve is associated with increased pressure within the eye, known as intraocular pressure (IOP). However, glaucoma can also occur without elevated IOP, known as normal-tension glaucoma.

When the pressure inside the eye becomes elevated, it can cause compression and damage to the retinal fibers that make up the optic nerve. These fibers are responsible for transmitting visual signals to the brain, allowing us to see.